Trial Profile
A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2, 4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined with Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs DTaP-hepatitis B vaccine (Primary) ; DTaP vaccine; Hepatitis B vaccine
- Indications Diphtheria; Hepatitis B; Pertussis; Tetanus
- Focus Pharmacodynamics; Registrational
- Sponsors LG Life Sciences
- 20 Jul 2013 New trial record